Index

absorption, distribution, metabolism, and excretion (ADME), 127
“active” controlled trials (ACTs), 94, 96, 112, 115
assay sensitivity arguments against, 99–100
first assay sensitivity argument against, 100–106
versus placebo-controlled trials (PCTs), 97–9, 113
“active” placebos, 71, 72
actuarial judgment, 171
acupuncture, therapeutic theory for, 94
acupuncture placebos, illegitimate, 89–94
acupuncture points, 89
additivity, 107–9, 111
allocation bias, 42, 43
American Journal of Psychiatry, 71
amiloride, 91
amphetamine, 110
Annals of Internal Medicine, 4, 71
antenatal steroids, use of, 161–2
antiarrhythmic drugs, 4, 16, 26
action, mechanisms involved in, 127–8
trials, 191
Archives of General Psychiatry, 71
ascorbic acid, 35–6
aspirin, 51, 73, 75, 132
assay sensitivity, 99
arguments against ACTs, 98, 115, 116
limited scope of, 100–106
PCTs problems with, 99
augmented interaction, 179

Baby and Child Care, 137
baseline differences, 34
“belief” effects, 67
benign unmasking, 78
benoxaprofen, 27, 54
benzpyrene, 132
biochemical mechanisms, 136, 140
block randomization, 60
bloodletting, 136–7
British Journal of Psychiatry, 71
British Medical Journal, 4, 21, 71
buprenorphine, 67
Cardiac Arrhythmia Suppression Trial (CAST), 16–17, 124
caregivers, 44, 64, 65, 70
confounding factors from, 46–7
knowledge, 67–9, 76, 77
masking, 66
Cartwright, N., 40, 126, 129, 147, 148, 149
causal claims, establishing, 130
Russo F and Williamson J
“historical” argument of, 133–4
“theoretical” argument of, 134–6
Cell, 153
Chalmers, Iain, 12, 20, 61
Chalmers, Tom, 14
chicken soup-type treatments, 152–3
cholera, eliminating, 132
cholesterol-lowering drugs, 27–8, 80–81
cimetidine, 100, 109
claims, of EBM philosophy, 8
classical hypothesis testing, 49, 61–2, 114, 134
clinical effectiveness, evidence for, 24, 25
harms, outweighing, 25–7
patient-relevant outcomes, 25
treatment, as best option, 28–9
clinical judgment versus mechanical prediction, 170–71
clinical medicine, mechanisms and roles in, 146
mechanism-based subgroup analysis, problem with, 150–51
mechanism-generated hypothesis, 151–3
results, generalization of, 147–50
closed circuit television (CCTV), 147, 148, 149–50
co-amilofruse, 91
Cochrane Collaboration, 162
comparative clinical studies, 4, 124–7, 154–7
comparative effectiveness research (CER), 28
concealed random allocation, 43–5
“conditioning effects”, see “belief” effects
confounding factors
and plausible rival hypotheses, 33–8
properties, 35–6
CONSORT (Consolidated Standards of Reporting Trials), 65–6
control groups, 35
critical appraisal, “new” level of, 189–91
cystathionine synthesis, 139
data collectors, 65
definition, of EBM, 15–20, 21–3
dexamethasone, 34, 35
“difference-making” evidence, 124
double blinding, see double masking
double masking, 40, 47, 65–6, 119–20, 187
confounding factors, 66–9
non-confounding factors, 77
Philip’s paradox, 78–9
full solution to to, 76–8
one (and a half) solutions to, 75–6
problems with, 63–5
successful masking, importance of, 69
problems and solutions to tests for, 73–5
terminology clarification, 65–6
dystonia, 132
encaainide, 17, 124
endorphin, 87–8
epinephrine, 5, 76, 87–8
exercise placebos, illegitimate, 87–9
“expectation effects”, see “belief” effects
expert clinical judgement, 158–61
and mechanical rule-following,
comparison between, 168–76
expertise, 176–82, 188
patient values and circumstances integration, 177–8
placebo effect, enhancing, 179–81
as a skill, 181–2
expertise/expert judgment, roles for, 160–61
external validity, problem of
employing mechanisms to, 147–50
Finlay, Carlos, 132
first assay sensitivity arguments against ACTs, 98–103
Fisher’s hypothesis tests, 144
flavivirus, 132
flecainide, 17, 124, 140
fluoxetine hydrochloride, 82, 86, 166
frusemide, 91
gathering, appraising, and implementing evidence, skills required in, 181–2
general clinical judgment, 160
at the bottom of (or off) hierarchy of evidence, 161–7
-genetic mechanism, 123
germ theory of disease, 151–2
GOBSAT (“Good Old Boys Sat Around the Table”) method, 159, 161
goiter, 144
“good” evidence, features of, 29–30
GRADE (Grading of Recommendations Assessment, Development and Evaluation) system, 55, 154
for ranking evidence, 29–30

-group judgment methods, 16
Guyatt, Gordon, 15, 148
Halsted radical mastectomy, 26, 165
Haynes, Brian, 15
Helicobacter pylori, 130, 135
hepatitis B immunization, 145
hierarchy of evidence, 5, 58
general clinical judgment at, 161–7
individual clinical judgment at, 167–76
high-quality mechanistic reasoning, 143–6, 154, 188
hormone replacement therapy (HRT), 40–41, 42, 47, 51, 53, 56
humorism, 137
ibuprofen, 93, 177
illegitimate exercise placebos, 87–9
individual clinical judgment, 160
at the bottom of the hierarchy, 167–76
industry-sponsored trials, 189, 190
infant mortality, 11, 12, 18, 137, 161, 191
integrating expertise, 160
International Conference on
Harmonization (ICH) E10
document, 97
irrational human conduct, 173
Jacobsen, Lenore, 68
Jenner, Edward, 132
Journal of Biological Chemistry, 153
Journal of Clinical Investigation, 13, 153
Journal of Clinical Psychiatry, 71
Journal of Experimental Medicine, 153
Journal of the American Medical Association, 4, 71, 162
ketorolac, 67
La Caze, 147, 151
legitimate placebo controls, 81, 82–3, 94–5
second condition for legitimacy, violating, 86–7
first condition for legitimacy, violating, 83–6
Leibovici’s hypothesis, 133–4, 146
limited interaction, 179
Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study, 26–7
low-quality mechanistic reasoning, 145–6
malicious unmasking, 78
manuscript authors, 65, 66, 191
mechanical rule-following and expert clinical judgment, comparison between, 168–76
mechanical rules versus clinical judges, 164–7
mechanical theory of causation (MTC), 122
mechanism-based subgroup analysis, problem with, 150–51
mechanism-generated hypothesis, 151–3
mechanistic reasoning, 4, 125–6, 128–30, 188
assumptions for, 148–9
causal claims establishment, 130
“historical” argument, of Russo and Williamson, 130–34
“theoretical” argument, of Russo and Williamson, 134–6
comparative clinical study, 124–6
positive and negative effects, on disorders, 154–6
definition, 127–8
delayed acceptance of therapies, 157
epistemological problems, 136
stochastic and complex mechanisms, 140–43
unknown mechanisms, 136–40
and expert judgment, 120–21
high-quality mechanistic reasoning, 143–6
mechanisms and roles, in clinical medicine, 125, 126–8, 146
mechanism-based subgroup analysis, problem with, 150–51
mechanism-generated hypothesis, 151–3
problem of external validity, employing mechanisms to, 147–50
role of, 153
tension between proponents of, 122–4
medical training, 189
medicine, history of, 3–7
metabolic mechanisms, 138–40
metamizol, 67
Mill’s methods, 124
motivation for birth, of EBM, 11–15
myocardial infarction, 124, 126, 138
naloxone, 111
Nature, 153
New England Journal of Medicine, 71
New York Times, 4
1948 streptomycin trial, 44, 61
nocebo effects, 72
n-of-1 trials, 55
non-fatal cardiac arrest, 124
non-placebo components, 108
non-steroidal anti-inflammatory drugs (NSAIDs), 92, 190
normal placebos, 71
“numerical” method, 124
O-acetyl-L-homoserine, 139
observational studies, 29–30, 36, 39
definitions and problems, 40–42
versus randomized trials, 48–9, 51–9, 187–8
observer bias, 67
olive oil placebos, 80–81, 86, 95
Opren, 27, 54
Orafl ex, 27, 54
Osler, William, 137
Ottawa ankle rule, 171–2
outcome evaluators, 65, 66, 74

paradoxical response, 141, 142, 144, 148
paradox of effectiveness, 39–40, 119, 187
classical hypothesis testing, logic of, 61–2
definition and problems, 40–42
high- and low-quality comparative clinical studies, distinguishing, 59–60
observational studies, 40–42
overcoming, 56–9
randomization and probabilistic causality, 62
randomized trials, 43
concealing allocation, 43–5
control, 45
experimental design and ruling out performance bias, 45–8
self-selection bias and allocation bias, 43–5
restricted randomization, types of, 60
"partial" mechanisms
mechanistic reasoning based on, 139
participants, 43, 45–6, 55, 60, 65, 76–7, 81, 85, 86, 87, 110, 112, 179
confounding factors from, 66–9
Pasteur, Louis, 152
pathophysiological rationale, 4, 16
patient–practitioner relationship, 179
patient preference bias, see self-selection bias
patient-relevant outcomes, 25, 128–9, 138, 187
patient values and circumstances integrating, 120, 121, 160, 177–8
penicillin, 5, 11
Percival Pott’s hypothesis, 132
performance bias, 35, 42, 45–8, 51, 66
Philip’s paradox, 63
and double masking, 78–9
full solution, 76–8
one (and a half) solutions, 75–6
phosphoenolpyruvate and acetyl-CoA, association between, 123
placebo-controlled trials (PCTs), 71, 97
absolute effect size, 107–12
assay sensitivity arguments against, 99–100
epipistemological foundations of ethical database, 96–8
first assay sensitivity argument against, 98–106
over ACTs, 97
second assay sensitivity argument, 106–7
smaller sample size, 112–13
versus “active” controlled trials, 96, 98
placebo controls, 40, 46, 47–8, 80
first condition for legitimacy, violating, 83–6
illegitimate acupuncture placebos, 89–94
illegitimate exercise placebos, 87–9
legitimate control, 82–3
need, 80–82
problem with illegitimate placebo controls, solution to, 94–5
second condition for legitimacy, violating, 86–7
placebo effect, 5, 28, 36, 69, 81, 86–7, 92, 100, 120, 124, 142, 161, 164, 166
enhancing, 179–81
unexpected effects of, 142
plausible rival hypotheses, ruling out, 33
and confounding factors, 33–8
Popper’s falsification, 144
Pott, Percival, 132
The Principles and Practice of Medicine, 137
protein synthesis, mechanism of, 122–3
Prozac therapy, 5, 82, 85, 95
pseudo-random methods, 43
publication bias, 59, 101, 189
publicly sponsored trials, 189
Pygmalion experiment, 68–9
Qi, 89, 92
rabies vaccine, 5, 11, 152
radiotherapy, 144
randomization, 43, 49–51
and probabilistic causality, 62
restricted, 43, 60
stratified, 60
weighted, 60
randomized pragmatic trials, 46
randomized trials, 4, 6, 39
concept, 40
control, 45
experimental design, 45–8
and GRADE system, 29–30
versus observational studies, 48, 187–9
high- and low-quality comparative clinical studies, distinguishing, 59–60
treatment benefits, exaggerating, 51–4
validity, 54–5
Worrall’s critique, 49–51
random allocation, 43–5
real treatment effects and natural history, confusion between, 166
relative risk reduction, 26, 27
relaxation response, 89
Russo and Williamson, 147
“historical” argument, 130–34
“theoretical” argument, 134–6
Sackett, Dave, 13, 15, 21, 73, 74, 75, 160
Science, 153
second assay sensitivity argument for ACTs and PCTs, 106–7
Second International Study of Infarct Survival (ISIS-2), 150
selection bias, 34, 41, 51, 56
selective serotonin reuptake inhibitors (SSRIs), 59, 101–2, 104
self-proclaimed Kuhnian paradigm, EBM as, 10–11
self-selection bias, 40, 41, 43–4, 51, 52, 119
Semmelweis’ hypothesis, 133, 135, 146, 151
17-point Hamilton Rating Scale for Depression (HRSD17), 88
sham acupuncture, 90, 92, 95
sham device, 90–91
sham surgery, 72, 87
side-effects, bias in, 25–7, 59, 70, 71–2, 74, 85, 104, 142, 155, 190
sildenafil, 142
skills required in gathering, appraising, and implementing evidence, 181–2
sleeping position, and SIDS relationship between, 137–8
smallpox vaccines, 132
Snow, John, 132
sodium fluoride, 51
source bias, 101
statisticians, 6, 37, 64, 65, 66, 190
stochastic and complex mechanisms mechanistic reasoning, problem with, 140–43
Streitberger needle therapy, 90–91, 92, 93, 94, 179
streptomycin, 11, 44–5, 61
structure, of book, 8–9
sudden infant death syndrome (SIDS), 144, 154
and sleeping position, 137–8
sulfinpyrazone, 73, 74, 75
superiority trial, 102–4, 115, 116
systematic bias, 101
“theoretical” argument, of Russo and Williamson
causal claims establishment, mechanistic reasoning for, 132, 134–6
therapeutic expertise, 160
Tourette’s syndrome, 132
tramadol, 67
transient ischaemic attacks (TIA) study, 73, 74, 75
type I error, 115–16
type II error, 115–16
ventricular extra beats (VEBs), 126–7, 138, 140
Viagra, 141
Vibrio cholerae, 132
vitamin C, 35, 45, 55, 62, 65
vitamin E, 51
Worrall, J, 26–7, 37, 48, 49–51, 52, 54, 55, 61–2
yellow fever, eliminating, 132